



TORII PHARMACEUTICAL CO., LTD.  
SHIONOGI Group Company

Tokyo, September 19, 2025

**FOR IMMEDIATE RELEASE**

**Torii Receives Manufacturing and Marketing Approval  
of YCANTH® (Cantharidin) topical solution 0.71%  
for the Treatment of Molluscum Contagiosum in Japan**

Torii Pharmaceutical Co., Ltd. (Torii) announced that Torii has today received manufacturing and marketing approval of YCANTH® (cantharidin) topical solution 0.71% for the treatment of Molluscum Contagiosum in Japan.

YCANTH® (cantharidin) topical solution 0.71% is a skin disease treatment drug containing cantharidin as an active ingredient. In the Phase 3 clinical study of YCANTH® (cantharidin) topical solution 0.71% in patients with molluscum contagiosum (≥2 years old) in Japan, the primary endpoint of efficacy has met superiority to the vehicle. Furthermore, the safety of YCANTH® (cantharidin) topical solution 0.71% was confirmed and there were no observed issues of tolerability for the application.

Torii expects YCANTH® (cantharidin) topical solution 0.71% to be a new option for the treatment of molluscum contagiosum patients (≥2 years old) in Japan.

Separately, Verrica received approval from the U.S. Food and Drug Administration in July 2023 for the topical treatment of molluscum contagiosum in adult and pediatric patients (≥2 years old) and launched YCANTH in the US in August 2023. Verrica and Torii are in process of further developing YCANTH® for additional indications, including a planned global clinical program in common warts, targeted to begin enrollment in the US by the end of 2025.

< Outline of Approval >

Product name	YCANTH® topical solution 0.71%
Japanese Accepted Name	Cantharidin
Indications	Molluscum Contagiosum
Dosage and administration	For adults and pediatric patients (≥2 years old), apply an appropriate amount of solution to the affected area once every 3 weeks during treatment. 16 to 24 hours after application, washing affected area with soap.

**ABOUT Molluscum Contagiosum**

Molluscum contagiosum is a highly prevalent, contagious dermatologic disease that often occurs in children due to infection with the molluscum contagiosum virus, a member of the poxviridae family, and is commonly referred to as "water warts." Many shiny papules with a diameter of 1 to 4 mm are seen on the trunk and extremities.

**ABOUT Common Warts**

Common warts (Verruca vulgaris) is a common dermatologic disease caused by infection with the human papillomavirus, and is commonly called “warts”. Keratinized raised lesions measuring several mm to 1 cm are seen mainly on the hands and feet.

Contact for Torii Pharmaceutical Co., Ltd.:  
Corporate Planning Department  
(Public Relations)  
Torii Pharmaceutical Co., Ltd.  
Tokyo: +81-3-3231-6814  
E-mail: [webmaster@torii.co.jp](mailto:webmaster@torii.co.jp)